CA3074876A1 - Combination therapies for inhibition of polo-like kinase 4 - Google Patents

Combination therapies for inhibition of polo-like kinase 4 Download PDF

Info

Publication number
CA3074876A1
CA3074876A1 CA3074876A CA3074876A CA3074876A1 CA 3074876 A1 CA3074876 A1 CA 3074876A1 CA 3074876 A CA3074876 A CA 3074876A CA 3074876 A CA3074876 A CA 3074876A CA 3074876 A1 CA3074876 A1 CA 3074876A1
Authority
CA
Canada
Prior art keywords
inhibitor
cancer
immune checkpoint
pharmaceutical composition
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3074876A
Other languages
English (en)
French (fr)
Inventor
Jacqueline M. Mason
Mark R. Bray
Tak Wah Mak
Graham Fletcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of CA3074876A1 publication Critical patent/CA3074876A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3074876A 2017-09-08 2018-09-07 Combination therapies for inhibition of polo-like kinase 4 Pending CA3074876A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555718P 2017-09-08 2017-09-08
US62/555,718 2017-09-08
PCT/CA2018/051086 WO2019046949A1 (en) 2017-09-08 2018-09-07 POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE

Publications (1)

Publication Number Publication Date
CA3074876A1 true CA3074876A1 (en) 2019-03-14

Family

ID=65633360

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3074876A Pending CA3074876A1 (en) 2017-09-08 2018-09-07 Combination therapies for inhibition of polo-like kinase 4

Country Status (8)

Country Link
US (1) US12109215B2 (https=)
EP (1) EP3678669A4 (https=)
JP (2) JP7343483B2 (https=)
CN (1) CN111225670A (https=)
AU (2) AU2018328773B2 (https=)
CA (1) CA3074876A1 (https=)
TW (1) TWI845482B (https=)
WO (1) WO2019046949A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
JP2023505301A (ja) * 2019-12-06 2023-02-08 ユニバーシティー ヘルス ネットワーク 急性骨髄性白血病または骨髄異形成症候群に対する治療
US20230165871A1 (en) * 2020-04-06 2023-06-01 University Health Network Combination therapies for inhibition of polo-like kinase 4
MX2023013225A (es) 2021-05-11 2024-01-15 Oric Pharmaceuticals Inc Inhibidores de la cinasa 4 similar a polo.
WO2022266240A1 (en) * 2021-06-16 2022-12-22 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5442906B2 (ja) * 2010-04-06 2014-03-19 ユニバーシティ・ヘルス・ネットワーク キナーゼインヒビターおよびこれを用いた癌の治療方法
US8933070B2 (en) * 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
RS58413B1 (sr) * 2013-10-18 2019-04-30 Univ Health Network So i kristalni oblici inhibitora plk-4
SG11201602882VA (en) * 2013-10-18 2016-05-30 Univ Health Network Treatment for pancreatic cancer
ES2686549T3 (es) * 2014-06-16 2018-10-18 Worldwide Innovative Network Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
AU2015327868A1 (en) * 2014-10-03 2017-04-20 Novartis Ag Combination therapies
EP3981430A1 (en) * 2015-01-21 2022-04-13 Memorial Sloan Kettering Cancer Center Methods and compositions for increasing susceptibility to radiation treatment by inhibiting suppression of numerical chromosomal instability of cancer cells
AU2016219204B2 (en) * 2015-02-12 2021-01-21 Beyondspring Pharmaceuticals, Inc. Use of Plinabulin in combination with immune checkpoint inhibitors

Also Published As

Publication number Publication date
WO2019046949A1 (en) 2019-03-14
AU2018328773B2 (en) 2023-11-16
JP2020533293A (ja) 2020-11-19
US20210060026A1 (en) 2021-03-04
US12109215B2 (en) 2024-10-08
JP7343483B2 (ja) 2023-09-12
EP3678669A4 (en) 2021-06-09
TW201919637A (zh) 2019-06-01
EP3678669A1 (en) 2020-07-15
CN111225670A (zh) 2020-06-02
TWI845482B (zh) 2024-06-21
AU2018328773A1 (en) 2020-03-26
AU2024200937A1 (en) 2024-02-29
JP2023155459A (ja) 2023-10-20

Similar Documents

Publication Publication Date Title
AU2022200196B2 (en) Methods, compositions, and kits for treatment of cancer
AU2024200937A1 (en) Combination therapies for inhibition of Polo-like Kinase 4
CN107743401B (zh) 包含抗pd-1抗体和另外的抗体的组合的组合物
JP2023039448A (ja) がんを治療するための、ｐｄ－１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
KR20200142542A (ko) Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법
US20160031990A1 (en) Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
US12110337B2 (en) Anti-CD27 antibodies and uses thereof
CA3114955A1 (en) Combination therapy for cancer
US20230390294A1 (en) Combination therapies for inhibition of ttk protein kinase
CN111973739A (zh) 抗pd-l1单克隆抗体治疗癌症的用途
EP3893888A1 (en) Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
CN115087461A (zh) 使用pd-1拮抗剂、ilt4拮抗剂和化学治疗剂的组合治疗癌症的方法
US20230192856A1 (en) Dosing and administration of activatable anti-ctla-4 antibody
CN113164599B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
WO2023192478A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
CN118829446A (zh) 使用ctla-4和pd-1双特异性抗体的治疗方法
KR20240153603A (ko) Ctla-4 및 pd-1 이중특이적 항체를 사용한 치료 방법

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230906

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240830

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240830

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240830

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240916

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250213

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250218

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250218

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250924

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260224